Analyst Rating
based on 2 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 2 analysts offering long term price targets for Marksans Pharma Ltd. An average target of ₹240
Source: S&P Global Market Intelligence
Marksans Pharma Ltd Share analysis
Marksans Pharma Ltd price forecast by 2 analysts
Downside of
High
₹265
Target
₹240.00
Low
₹215
Marksans Pharma Ltd target price ₹240, a slight downside of -8.78% compared to current price of ₹263.09. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Marksans Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:0
Forecast
Actual
Including amortisation and stock based compensations
Marksans Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:0
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹261.75₹278.752 Week's Low
52 Week's High
₹97.45₹278.7
| Returns % | |
| 1 Month Return | + 32.51 % |
| 3 Month Return | + 68.38 % |
| 1 Year Return | + 143.94 % |
| Market Stats | |
| Previous Close | ₹259.00 |
| Open | ₹268.05 |
| Volume | 1.08Cr |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹11,736.94Cr |
Key Statistics
| P/E Ratio | 35.7 |
| PEG Ratio | 44.62 |
| Market Cap | ₹11,736.94 Cr |
| P/B Ratio | 2.87 |
| EPS | 6.95 |
| Dividend Yield | 0.71 |
| Sector | Pharmaceuticals |
| ROE | 11.46 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹11,736.94 Cr | 316.22% | 0.50 | ₹314 Cr | ₹2,177 Cr | |
| BUY | ₹4,215.47 Cr | 7.77% | 0.63 | ₹94 Cr | ₹1,081 Cr | |
| NA | ₹521.96 Cr | 32.07% | 0.51 | NA | NA | |
| NA | ₹326.38 Cr | 145.42% | 0.66 | ₹5 Cr | ₹155 Cr | |
| HOLD | ₹27,865.02 Cr | 33.47% | 0.53 | ₹715 Cr | ₹2,707 Cr |
Company Information
Share Price: ₹263.09 per share as on 06 Sep, 2024 04:01 PM
Market Capitalisation: ₹11,736.94Cr as of today
Revenue: ₹590.62Cr as on June 2024 (Q2 24)
Net Profit: ₹89.07Cr as on June 2024 (Q2 24)
Listing date: 21 Jan, 2002
Chairperson Name: Mark Saldanha
| Organisation | Marksans Pharma Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Marksans Pharma Ltd
Marksans Pharma Reports Strong Financial Performance - 05 Sep, 2024
Marksans Pharma Limited shows robust financial health with a market cap of ₹118.41 billion, earnings growth of 21.7%, and a reduced debt-to-equity ratio. Recent Q1 results indicate net income growth, reflecting potential for future growth through M&A activities in Europe.
Marksans Pharma Achieves 52-Week High on Strong Results - 21 Aug, 2024
Marksans Pharma's stock reached a 52-week high following strong quarterly earnings and the UKMHRA's approval of three Fluoxetine products by its subsidiary Relonchem.
Marksans Pharma Receives Positive USFDA Inspection Report - 20 Aug, 2024
Marksans Pharma announced the receipt of an Establishment Inspection Report (EIR) from the USFDA for its Goa facility, classified as Voluntary Action Indicated (VAI). The inspection has been successfully closed. The company also reported a significant increase in net profit and revenue for Q1 FY25, indicating strong performance.
Marksans Pharma Reports Strong Q1 Results - 15 Aug, 2024
Marksans Pharma's Q1 results show a 29.27% YoY profit increase and an 18.12% rise in topline. The company has a market cap of ₹9712.66 Cr and a consensus Strong Buy rating from analysts.
Marksans Pharma Reports Strong Q1 Earnings Growth - 14 Aug, 2024
Marksans Pharma shares surged following a strong Q1 FY25 performance, with a 26% increase in profit and 18% revenue growth. The company remains optimistic about future growth driven by new product launches and favorable market conditions.
Insights on Marksans Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 78.29 Cr → 88.75 Cr (in ₹), with an average increase of 11.8% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 576.54 Cr → 605.57 Cr (in ₹), with an average increase of 4.8% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 43.85% to 43.87% in Jun 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 4.69% to 7.71% in Jun 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, MARKSANS stock has moved up by 9.6%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 35.40% to 33.78% in Jun 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 4.23% to 2.82% in Jun 2024 quarter
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 43.87% | 0.06 | |
| Foreign Institutions | 7.71% | 64.49 | |
| Mutual Funds | 2.81% | ||
| Retail Investors | 33.78% | ||
| Others | 11.82% |
Key Indicators
Marksans Pharma Ltd Valuation
Marksans Pharma Ltd in the last 5 years
Lowest (4.67x)
April 1, 2020
Today (35.70x)
September 6, 2024
Industry (59.14x)
September 6, 2024
Highest (46.60x)
January 24, 2018
Earnings and Dividends
Marksans Pharma Ltd Earnings Results
Marksans Pharma Ltd’s net profit jumped 29.26% since last year same period to ₹88.75Cr in the Q1 2024-2025. On a quarterly growth basis, Marksans Pharma Ltd has generated 13.36% jump in its net profits since last 3-months.
Read More about Earnings ResultsMarksans Pharma Ltd Dividends May,2023
In the quarter ending March 2023, Marksans Pharma Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.29%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Marksans Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Marksans Pharma Ltd shares.
Marksans Pharma Ltd (MARKSANS) share price today is ₹263.09
Marksans Pharma Ltd is listed on NSE
Marksans Pharma Ltd is listed on BSE
- Today’s highest price of Marksans Pharma Ltd is ₹278.7.
- Today’s lowest price of Marksans Pharma Ltd is ₹261.75.
PE Ratio of Marksans Pharma Ltd is 35.7
PE ratio = Marksans Pharma Ltd Market price per share / Marksans Pharma Ltd Earnings per share
Today’s traded volume of Marksans Pharma Ltd(MARKSANS) is 1.08Cr.
Today’s market capitalisation of Marksans Pharma Ltd(MARKSANS) is ₹11736.94Cr.
| Marksans Pharma Ltd(MARKSANS | Price |
|---|---|
52 Week High | ₹278.7 |
52 Week Low | ₹97.45 |
Marksans Pharma Ltd(MARKSANS) share price is ₹263.09. It is down -5.60% from its 52 Week High price of ₹278.7
Marksans Pharma Ltd(MARKSANS) share price is ₹263.09. It is up 169.97% from its 52 Week Low price of ₹97.45
| Marksans Pharma Ltd(MARKSANS | Returns |
|---|---|
1 Day Returns | 4.09% |
1 Month Returns | 32.51% |
3 Month Returns | 68.38% |
1 Year Returns | 143.94% |